tiprankstipranks
Trending News
More News >
Atai Life Sciences N.V. (ATAI)
:ATAI
Advertisement

ATAI Life Sciences (ATAI) AI Stock Analysis

Compare
1,825 Followers

Top Page

ATAI

ATAI Life Sciences

(NASDAQ:ATAI)

Select Model
Select Model
Select Model
Neutral 54 (OpenAI - 4o)
Rating:54Neutral
Price Target:
$6.00
▲(3.99% Upside)
ATAI Life Sciences' overall stock score is primarily impacted by its poor financial performance, characterized by ongoing losses and negative cash flows. The technical analysis provides some positive momentum, but the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events limits additional insights.
Positive Factors
Strategic Acquisitions
The acquisition of Beckley Psytech aims to create a market leader in psychedelic mental health therapies, enhancing ATAI's competitive position and accelerating its development pipeline.
Financing Agreement
The $50M PIPE financing supports ATAI's operations and clinical programs, providing financial stability and enabling continued investment in its therapeutic pipeline.
Pipeline Development
Positive Phase IIb results for BPL-003 in treatment-resistant depression support advancing to Phase III, indicating strong potential for future product offerings and market expansion.
Negative Factors
Negative Cash Flows
Persistent negative cash flows highlight inefficiencies in cash management and reliance on external financing, posing risks to long-term operational sustainability.
Profitability Challenges
Ongoing profitability challenges with negative earnings indicate significant cost pressures and difficulty in generating revenue, impacting long-term financial health.
Revenue Growth Issues
Lack of revenue growth highlights challenges in market penetration and product adoption, potentially limiting future financial performance and competitive positioning.

ATAI Life Sciences (ATAI) vs. SPDR S&P 500 ETF (SPY)

ATAI Life Sciences Business Overview & Revenue Model

Company DescriptionATAI Life Sciences is a biotechnology company focused on the development of innovative treatments for mental health disorders. Operating in the life sciences sector, ATAI aims to transform the mental health landscape by leveraging advanced therapeutics and psychedelic compounds. The company collaborates with various entities to create a diverse pipeline of products, including novel therapies for conditions such as depression, anxiety, and addiction.
How the Company Makes MoneyATAI Life Sciences generates revenue primarily through the development and commercialization of its therapeutic products. The company partners with pharmaceutical firms, research institutions, and other stakeholders to co-develop its drug candidates, which can lead to milestone payments and royalties upon successful commercialization. Additionally, ATAI may receive funding from grants or investments aimed at supporting its research initiatives. Strategic partnerships with larger pharmaceutical companies can also provide substantial financial backing, facilitating further research and development while sharing potential profits from successful product launches.

ATAI Life Sciences Financial Statement Overview

Summary
ATAI Life Sciences faces significant financial challenges, marked by ongoing losses and lack of revenue growth. Despite a low leverage position, negative cash flows and earnings pose substantial risks. Financial sustainability relies heavily on external funding.
Income Statement
25
Negative
ATAI Life Sciences has consistently faced challenges with profitability, as indicated by negative EBIT and net income figures across all reported years. The absence of revenue growth further underscores the company's struggle to generate revenue. The gross profit remained negative or negligible, pointing towards significant cost pressures and lack of revenue generation capabilities.
Balance Sheet
40
Negative
The company's balance sheet shows a high level of equity in comparison to its total assets, with an improving trend in stockholders' equity, despite negative earnings. The debt-to-equity ratio is relatively low, suggesting conservative leverage use. However, the continued accumulation of losses poses a risk to financial stability over time.
Cash Flow
35
Negative
ATAI Life Sciences has struggled to generate positive cash flows, with negative operating and free cash flows reported consistently. The cash flow to net income ratios indicate inefficiencies in cash management. The company's ability to sustain operations heavily depends on external financing, evident from periodic positive financing cash flows.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue2.31M308.00K314.00K233.00K20.38M0.00
Gross Profit2.31M308.00K314.00K65.00K20.33M-24.00K
EBITDA-115.81M-145.33M-36.31M-135.01M-120.28M-92.12M
Net Income-119.40M-149.27M-40.22M-141.41M-132.61M-102.12M
Balance Sheet
Total Assets189.20M159.39M293.48M305.44M414.17M111.55M
Cash, Cash Equivalents and Short-Term Investments95.94M62.33M179.26M273.11M362.27M97.25M
Total Debt9.22M24.71M19.14M15.12M743.00K2.18M
Total Liabilities45.28M42.83M49.16M300.42M28.21M16.18M
Stockholders Equity143.74M116.30M242.96M260.74M376.91M90.82M
Cash Flow
Free Cash Flow-80.79M-82.53M-84.71M-105.49M-64.37M-20.82M
Operating Cash Flow-75.57M-82.44M-84.12M-104.47M-63.25M-20.77M
Investing Cash Flow30.17M59.17M-53.30M-86.85M-81.28M-28.27M
Financing Cash Flow72.41M5.37M-8.36M20.79M409.86M113.05M

ATAI Life Sciences Technical Analysis

Technical Analysis Sentiment
Positive
Last Price5.77
Price Trends
50DMA
5.04
Positive
100DMA
4.02
Positive
200DMA
2.83
Positive
Market Momentum
MACD
0.25
Positive
RSI
54.70
Neutral
STOCH
31.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATAI, the sentiment is Positive. The current price of 5.77 is above the 20-day moving average (MA) of 5.60, above the 50-day MA of 5.04, and above the 200-day MA of 2.83, indicating a bullish trend. The MACD of 0.25 indicates Positive momentum. The RSI at 54.70 is Neutral, neither overbought nor oversold. The STOCH value of 31.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATAI.

ATAI Life Sciences Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
74
Outperform
$1.21B5.90799.36%
58
Neutral
$4.21B-14.16-60.98%338.45%-19.64%
54
Neutral
$1.51B
54
Neutral
$1.14B-440.80%-19.56%35.55%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
43
Neutral
$1.12B-171.41%-14.98%-51.76%
43
Neutral
$1.21B-43.82%-7.33%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ATAI
ATAI Life Sciences
5.77
4.55
372.95%
NKTR
Nektar Therapeutics
60.10
39.70
194.61%
WVE
Wave Life Sciences
7.13
-7.86
-52.43%
ORIC
Oric Pharmaceuticals
13.10
4.65
55.03%
CVAC
CureVac
5.36
2.53
89.40%
PRAX
Praxis Precision Medicines
173.97
102.24
142.53%

ATAI Life Sciences Corporate Events

Private Placements and Financing
ATAI Life Sciences Closes $149.5 Million Public Offering
Positive
Oct 21, 2025

On October 20, 2025, atai Life Sciences announced the successful closing of its public offering of 27,283,750 common shares, raising approximately $149.5 million. The proceeds, along with existing cash resources, will fund the advancement of clinical trials for its product candidates, including the Phase 3 program for BPL-003 and Phase 2 trials for VLS-01 and EMP-01. This financing is expected to support operations into 2029, reflecting strong investor confidence in atai’s mission to transform mental health treatment.

The most recent analyst rating on (ATAI) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

Product-Related AnnouncementsRegulatory Filings and Compliance
ATAI Life Sciences’ BPL-003 Receives FDA Breakthrough Designation
Positive
Oct 16, 2025

On October 16, 2025, atai Life Sciences and Beckley Psytech announced that the U.S. FDA granted Breakthrough Therapy designation to BPL-003, an intranasal formulation for treatment-resistant depression. This designation, following positive Phase 2b trial results, highlights BPL-003’s potential to significantly improve depressive symptoms rapidly and durably, fitting into existing treatment paradigms. The designation is expected to expedite the development and regulatory review process, positioning BPL-003 for Phase 3 trials in 2026, and underscores the potential impact on patients and the mental health treatment landscape.

The most recent analyst rating on (ATAI) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

M&A Transactions
ATAI Life Sciences to Acquire Beckley Psytech
Neutral
Oct 10, 2025

ATAI Life Sciences N.V. has announced a share purchase agreement dated June 2, 2025, to acquire the remaining issued share capital of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other conditions. This acquisition could potentially enhance ATAI’s position in the mental health treatment industry, although there are risks related to the completion and benefits realization of the transaction.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

M&A Transactions
ATAI Life Sciences to Acquire Beckley Psytech Shares
Neutral
Sep 29, 2025

ATAI Life Sciences announced a share purchase agreement dated June 2, 2025, to acquire the remaining shares of Beckley Psytech Limited, a company based in England and Wales. The transaction is expected to close in the fourth quarter of 2025, pending shareholder approval and other customary conditions, potentially impacting ATAI’s market position and operational capabilities.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

Business Operations and StrategyProduct-Related Announcements
ATAI Life Sciences Announces Positive Phase 2a Study Results
Positive
Sep 23, 2025

On September 23, 2025, ATAI Life Sciences and Beckley Psytech announced positive results from a Phase 2a study of BPL-003, an intranasal formulation for treatment-resistant depression. The study demonstrated that a two-dose regimen of BPL-003 led to significant reductions in depression scores and improved remission rates, with sustained effects and a strong safety profile. These findings support further development and regulatory discussions for Phase 3 trials, potentially enhancing ATAI’s position in the mental health treatment industry.

The most recent analyst rating on (ATAI) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on ATAI Life Sciences stock, see the ATAI Stock Forecast page.

Atai Life Sciences Reports Q2 2025 Financial Results
Aug 15, 2025

Atai Life Sciences N.V. is a clinical-stage biopharmaceutical company focused on developing innovative treatments for mental health disorders, leveraging both psychedelic and non-psychedelic compounds. The company recently released its earnings report for the quarter ending June 30, 2025, highlighting its ongoing efforts in advancing its diverse pipeline of psychiatric product candidates.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Oct 23, 2025